Key points are not available for this paper at this time.
These model-based lead-time estimates support a prostate cancer screening interval of more than 1 year.
Draisma et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: